Quick, non-invasive and quantitative assessment of small fiber XXXX in @entity1 receiving chemotherapy.

@entity1 @entity901 @entity16 @entity1311 @entity1897 @entity2359
UNASSIGNED: @entity1897 ( @entity1897 ) is a common, potentially severe and dose-limiting adverse effect; however, it is poorly investigated at an early stage due to the lack of a simple assessment tool. As sweat glands are innervated by small autonomic C-fibers, sudomotor function testing has been suggested for early screening of @entity1897 . This study aimed to evaluate Sudoscan, a non-invasive and quantitative method to assess sudomotor function, in the detection and follow-up of @entity1897 . Eighty-eight @entity1 receiving at least two infusions of @entity901 only (45.4  %), @entity1311 only (14.8  %), another drug only (28.4  %) or two drugs (11.4  %) were enrolled in the study. At each chemotherapy infusion the accumulated dose of chemotherapy was calculated and the @entity16 Score clinical version (TNSc) was carried out. Small fiber @entity16 was assessed using Sudoscan (a 3-min test). The device measures the Electrochemical Skin Conductance (ESC) of the hands and feet expressed in microSiemens (  S). For @entity1 receiving @entity901 mean hands ESC changed from 73      2 to 63      2 and feet ESC from 77      2 to 66      3   S (p  <  0.001) while TNSc changed from 2.9      0.5 to 4.3      0.4. Similar results were observed in @entity1 receiving @entity1311 or another @entity2359 chemotherapy. During the follow-up, ESC values of both hands and feet with a corresponding TNSc  <  2 were 70      2 and 73      2   S respectively while they were 59      1.4 and 64      1.5   S with a corresponding TNSc  >=   6 (p  <  0.0001 and p  =  0.0003 respectively). This preliminary study suggests that small fiber @entity16 could be screened and followed using Sudoscan in @entity1 receiving chemotherapy.
